Macular Degeneration Trial, Recruiting NCT05355415 Sponsor: Food and Drug Administration (FDA) Condition: Macular Degeneration
Back to Macular Degeneration

Macular Degeneration Trial, Recruiting

NCT05355415
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 21 years of age or older
  • People who are able to follow simple instructions during eye imaging (similar to what a standard eye exam involves)
  • People who are able to understand and sign a consent form (note: the trial does not enrol people whose primary language is not English)
  • People who have been diagnosed with a disease or condition affecting the outer part of the retina (the back of the eye)

Who may not be able to join:

  • People who have a condition that prevents clear eye images from being taken, such as difficulty keeping the eye still or cloudiness in the eye (confirm with trial site)
  • People whose vision prescription falls outside the range of +4 to -8 diopters (a measure of lens strength used in glasses or contact lenses)
  • People who have had a bad reaction to eye drops used to widen the pupil (mydriatic drops)
  • People who have a tendency toward, or any history of, a sudden type of glaucoma called acute angle closure glaucoma, or who have a narrow drainage angle in the eye that may increase that risk
  • People who work directly under the supervision of the named study investigators (Drs. Hammer, Cukras, and Liu) or any of the NIH/NEI research team members listed on the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Daniel X Hammer, Ph.D., Food and Drug Administration (FDA)

Phone: 301-796-9320

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Food and Drug Administration (FDA)
Registry
ClinicalTrials.gov
Start date
27 August 2021
Est. completion
30 September 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Photoreceptor (PR) density; Retinal pigment epithelial (RPE) cell density; RPE cell organelle motility; PR cell function

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov